Perspectives on mTOR Inhibitors for Castration-Refractory Prostate Cancer

Author(s): Salvatore L. Burgio, Francesco Fabbri, Ian J. Seymour, Wainer Zoli, Dino Amadori, Ugo De Giorgi

Journal Name: Current Cancer Drug Targets

Volume 12 , Issue 8 , 2012

Become EABM
Become Reviewer


The phosphatidylinositol 3'-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway contributes to prostate cancer progression and transition to androgen-independent disease. Furthermore, recent microarray analysis demonstrates that this pathway is often deregulated during prostate cancer progression. Thus, targeting of PI3K/AKT/mTOR may present a promising therapy for castration-refractory prostate cancer (CRPC). In recent years, several interesting strategies have been developed that interfere with distinct components of the PI3K/AKT/mTOR cascade. This article discusses many of the mechanisms involved, specifically in the context of prostate cancer. In addition, we present an overview of preliminary data on the activity of mTOR inhibitors and on the key steps to evaluate which of these compounds are most suitable for the treatment of prostate cancer. Particular emphasis is also placed on the development of novel perspectives to improve the poor prognosis of patients with CRPC.

Keywords: AKT, hypoxia, mTOR, PI3K, prostate cancer, signaling, therapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [940 - 949]
Pages: 10
DOI: 10.2174/156800912803251234
Price: $65

Article Metrics

PDF: 13